Document is current
Any future updates will be listed below
-
Authors
Fu, Denggang
Jiang, Hua
Long, Alan https://orcid.org/0000-0002-9600-326X
Harris, Ella
Guo, Hongfen
Capitano, Maegan L.
Wrangle, John
Faust, Joshua R.
Gopalakrishnapillai, Anilkumar
Pasupuleti, Santhosh Kumar https://orcid.org/0000-0001-5770-7187
Ramdas, Baskar https://orcid.org/0009-0006-2206-5720
Kapur, Reuben https://orcid.org/0000-0003-2225-1700
Barwe, Sonali P. https://orcid.org/0000-0003-4162-3004
Cheung, Nai-Kong V. https://orcid.org/0000-0001-6323-5171
Paczesny, Sophie https://orcid.org/0000-0001-5571-2775
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA232491, P30 CA138313)
U.S. Department of Defense (W81XWH2210981)
- License Information
-
More Information
Article History
Received: 28 March 2024
Accepted: 18 June 2025
First Online: 14 July 2025
Competing interests
: N.-K.V.C. reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity in Y-Mabs Therapeutics Inc., holding ownership interest/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. N.-K.V.C. is the inventor and owner of issued patents licensed by Memorial Sloan Kettering Cancer Center (MSKCC) to Ymabs Therapeutics, Biotec Pharmacon, and Abpro-labs. Both MSKCC and N.-K.V.C. have financial interest in Y-mabs. N.-K.V.C. is an advisory board member for Abpro-Labs and Eureka Therapeutics. Otherwise, the authors declare that they have no competing interests.
